Heart failure is common and serious, affecting millions worldwide, including about 6.7 million adults in the United States (age 20+). Symptoms can vary by type—dyspnea on exertion is often reported in acute cases, while orthopnea is common in chronic HF. Diagnosis relies on clinical evaluation and testing such as BNP and echocardiography, and outcomes remain significant even after treatment. This page breaks down risk factors, diagnostic clues, and evidence-based therapies.
Key Takeaways
- Dyspnea on exertion is reported in 89% of acute heart failure presentations
- Orthopnea occurs in 78% of chronic heart failure patients
- Elevated BNP >100 pg/mL has 85% sensitivity for diagnosing heart failure
- In the United States, approximately 6.7 million adults aged 20 and older have heart failure as of 2024
- Globally, heart failure affects an estimated 64.34 million people in 2017, with projections to increase due to aging populations
- The incidence of heart failure is 950,000 new cases per year in the US among adults over 18
- 5-year mortality rate for heart failure is 50% post-diagnosis
- In-hospital mortality for acute HF is 4-7% in US registries
- HFrEF patients have 12% annual mortality vs 5% for HFpEF
- Hypertension is present in 80-90% of heart failure patients
- Diabetes mellitus increases heart failure risk by 2-5 fold
- Coronary artery disease accounts for 60-70% of heart failure etiologies in developed countries
- ACE inhibitors reduce mortality by 20-30% in HFrEF patients with EF<40%
- Beta-blockers (carvedilol) decrease hospitalizations by 35% in HF trials
- SGLT2 inhibitors (dapagliflozin) reduce HF hospitalizations by 27% in DAPA-HF trial
Related reading
01 · Category
Clinical Presentation20 stats
01
Dyspnea on exertion is reported in 89% of acute heart failure presentations
02
Orthopnea occurs in 78% of chronic heart failure patients
03
Elevated BNP >100 pg/mL has 85% sensitivity for diagnosing heart failure
04
Echocardiography shows ejection fraction <40% in 50% of HFrEF cases
05
Peripheral edema present in 65% of decompensated HF patients
06
S3 gallop detected in 40-50% of acute HF admissions via auscultation
07
NT-proBNP >300 pg/mL rules in HF with 99% specificity in non-acute settings
08
Chest X-ray shows cardiomegaly in 70% of HF patients with pulmonary congestion
09
Fatigue is a presenting symptom in 75% of ambulatory HF patients NYHA class II-III
10
Jugular venous distension observed in 68% of hospitalized HF patients
11
Paroxysmal nocturnal dyspnea in 50% of NYHA III-IV patients
12
Hepatomegaly in 15-20% of right-sided HF cases
13
Crackles on lung exam in 60% of acute HF with congestion
14
ECG shows Q waves in 30% of ischemic HF etiology
15
Peak VO2 <14 ml/kg/min indicates severe functional limitation in 70% of class III
16
Hyponatremia (<135 mEq/L) in 20% of hospitalized HF, diagnostic clue
17
Stress echo detects ischemia in 25% of new HF diagnoses
18
Cachexia in 10-15% of advanced HF, weight loss >6% in 6 months
19
Cough with frothy sputum in 10% of acute pulmonary edema cases
20
Elevated JVP >8cm predicts congestion with 80% accuracy
02 · Category
Epidemiology18 stats
01
In the United States, approximately 6.7 million adults aged 20 and older have heart failure as of 2024
02
Globally, heart failure affects an estimated 64.34 million people in 2017, with projections to increase due to aging populations
03
The incidence of heart failure is 950,000 new cases per year in the US among adults over 18
04
Prevalence of heart failure in Europe is about 1-2% of the adult population, rising to over 10% in those over 70 years
05
In the UK, heart failure prevalence is 1.53% overall, increasing to 14.4% in those aged 85+
06
Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of heart failure cases in the elderly
07
Annual incidence rate of heart failure in men is 10-19 per 1,000 person-years for ages 65-74
08
In sub-Saharan Africa, heart failure prevalence is 12.4 per 1,000 adults
09
Heart failure hospitalization rates in the US decreased by 33% from 2000 to 2014 but remain high at 185 per 100,000
10
Lifetime risk of developing heart failure is 20% for men and 19% for women at age 45
11
In the United States, heart failure prevalence has increased by 46% from 2000 to 2014
12
Age-adjusted HF incidence declined by 12% per decade from 1979-2009 in Olmsted County
13
HFpEF prevalence doubled from 20% to 50% of cases between 1990s and 2010s
14
In China, HF prevalence is 1.3% overall, 4.3% in >75 years
15
Black Americans have 1.8 times higher HF incidence than whites
16
Women develop HF 10 years later than men on average
17
Pediatric HF incidence is 11.4 per 100,000 in children <18 years
18
HF hospitalizations cost $30.7 billion annually in US (2012 data)
03 · Category
Prognosis And Mortality19 stats
01
5-year mortality rate for heart failure is 50% post-diagnosis
02
In-hospital mortality for acute HF is 4-7% in US registries
03
HFrEF patients have 12% annual mortality vs 5% for HFpEF
04
NYHA class IV patients have 30% 1-year mortality rate
05
Sudden cardiac death accounts for 25-50% of HF deaths
06
Post-hospitalization 30-day readmission rate for HF is 20-25%
07
EF <20% predicts 1-year mortality of 40% in advanced HF
08
Elevated troponin at admission triples 60-day mortality risk in acute HF
09
Renal dysfunction (eGFR<30) increases 1-year mortality by 2.5-fold
10
1-year mortality post-HF diagnosis is 29% for age 65+
11
HF accounts for 1 in 8 deaths in US (425,147 deaths in 2020)
12
Black patients have 50% higher HF mortality than whites
13
Peak VO2 <10 ml/kg/min predicts 1-year mortality >50%
14
6-minute walk <300m associated with 2-fold mortality increase
15
MAGGIC score >30 predicts 3-year mortality >50%
16
Hyponatremia at discharge doubles 1-year mortality risk
17
90-day mortality post-LVAD is 18% in INTERMACS registry
18
Women with HF have better survival than men (HR 0.85)
19
Cancer comorbidity increases HF mortality by 1.5-fold
Interpretation
Prognosis And Mortality Interpretation
Overall prognosis is poor in heart failure, with 50% mortality within 5 years after diagnosis and a notably higher annual death rate for HFrEF at 12% compared with 5% for HFpEF.
More related reading
04 · Category
Risk Factors18 stats
01
Hypertension is present in 80-90% of heart failure patients
02
Diabetes mellitus increases heart failure risk by 2-5 fold
03
Coronary artery disease accounts for 60-70% of heart failure etiologies in developed countries
04
Obesity (BMI >30) raises heart failure risk by 35% in men and 50% in women
05
Smoking doubles the risk of heart failure independently of coronary disease
06
Atrial fibrillation increases heart failure risk by 4-5 fold
07
Chronic kidney disease stage 3+ elevates heart failure risk by 2.5 times
08
Alcohol consumption >14 drinks/week increases cardiomyopathy risk leading to HF by 2.3-fold
09
Sleep apnea (AHI >30) associated with 2.4-fold higher HF incidence
10
Family history of cardiomyopathy increases HF risk by 2.5-fold in first-degree relatives
11
Hyperlipidemia contributes to HF risk via CAD in 40% of cases
12
Physical inactivity increases HF risk by 35%
13
Valvular heart disease causes 10-15% of HF cases
14
HIV infection raises HF risk 6-fold due to cardiomyopathy
15
Chemotherapy (anthracyclines) induces HF in 5-10% at cumulative doses >250mg/m2
16
Thyroid dysfunction (hypo/hyper) doubles HF risk
17
Depression associated with 40% higher HF incidence
18
Anemia (Hb<12g/dL) present in 30-50% of HF patients, worsening prognosis
05 · Category
Treatment Outcomes20 stats
01
ACE inhibitors reduce mortality by 20-30% in HFrEF patients with EF<40%
02
Beta-blockers (carvedilol) decrease hospitalizations by 35% in HF trials
03
SGLT2 inhibitors (dapagliflozin) reduce HF hospitalizations by 27% in DAPA-HF trial
04
ARNI (sacubitril/valsartan) lowers CV death by 20% vs enalapril in PARADIGM-HF
05
Mineralocorticoid antagonists (spironolactone) reduce mortality by 30% in RALES trial
06
ICD implantation reduces sudden death by 31% in MADIT-II trial for ischemic HF
07
CRT improves EF by 5-10% in 70% of responders with LBBB and QRS>150ms
08
Loop diuretics achieve symptom relief in 85% of acute decompensated HF within 24h
09
Ivabradine reduces HF hospitalizations by 18% in SHIFT trial for sinus rhythm patients
10
Exercise training improves peak VO2 by 2.2 ml/kg/min in HF-ACTION trial
11
Digoxin reduces HF hospitalizations by 28% in DIGITALIS trial
12
Vericiguat lowers CV death/HF hosp by 10% in VICTORIA trial
13
Finerenone reduces HF events by 13% in FIDELIO-DKD for CKD+HF
14
LVAD bridges to transplant in 50% of INTERMACS patients
15
Cardiac rehab improves quality of life scores by 10 points in HF-QOL
16
Omecamtiv mecarbil improves composite outcome by 8% in GALACTIC-HF
17
Sodium restriction <2g/day reduces readmissions by 20% in small trials
18
Telemonitoring reduces mortality by 15% in meta-analyses
19
Vaccination (influenza) lowers HF hospitalization by 18% in HF patients
20
Palliative care consultation improves symptoms in 80% of advanced HF
report visual · Key figures
Heart Failure Statistics statistics snapshot
Selected headline statistics from verified sources for a stable visual baseline.
89%
Dyspnea on exertion is reported in 89% of acute heart failure presentations
78%
Orthopnea occurs in 78% of chronic heart failure patients
85%
Elevated BNP >100 pg/mL has 85% sensitivity for diagnosing heart failure
40%
Echocardiography shows ejection fraction <40% in 50% of HFrEF cases
65%
Peripheral edema present in 65% of decompensated HF patients
-50%
S3 gallop detected in 40-50% of acute HF admissions via auscultation
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Heart Failure Statistics. Gitnux. https://gitnux.org/heart-failure-statistics
MLA
Isabelle Moreau. "Heart Failure Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/heart-failure-statistics.
Chicago
Isabelle Moreau. 2026. "Heart Failure Statistics." Gitnux. https://gitnux.org/heart-failure-statistics.
Sources & references
13 datasets cited across this report · attribution is report-level